HLN Haleon Plc

Haleon plc: Director Declaration

2 February 2024: In accordance with paragraph 9.6.14R of the Listing Rules of the UK Financial Conduct Authority, Haleon plc (LSE/NYSE: HLN) announces that Brian McNamara, Group Chief Executive Officer, has been appointed to the Board of Mondelēz International, Inc. (Nasdaq: MDLZ), as a Non-Executive Director with effect from 1 February 2024.

There is no further information to be disclosed in respect of paragraph 9.6.14.

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.